Clinical Trials Logo
  1. Home
  2. Biliary Tract Cancer
  3. NCT01861483
  4. Details
NCT01861483 Clinical Trial

Vessel Resection and Reconstruction of Biliary Tract Cancers

Biliary Tract Cancer Clinical Trial

Official title:
Resection and Reconstruction of Major Vessels in Biliary Tract Cancers

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01861483
Other study ID # KHBO1205
Secondary ID UMIN000010415
Status Completed
Phase N/A
First received May 14, 2013
Last updated June 29, 2014
Start date March 2013
Est. completion date March 2014

Study information
Verified date June 2014
Source Kansai Hepatobiliary Oncology Group
Contact n/a
Is FDA regulated No
Health authority Japan: Institutional Review Board
Study type Observational

Clinical Trial Summary

To investigate the vessel resection and reconstruction in biliary tract cancer.

Description:

The vessel resection and reconstruction of hepatic artery and portal vein in biliary tract cancer surgery is still controversial. In this study, we retrospectively evaluate the diagnostic image, pathology, peri-operative events, recurrence, and prognosis in these patients, as a multi-center surveillance.

Recruitment information / eligibility
Status Completed
Enrollment 100
Est. completion date March 2014
Est. primary completion date March 2014
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Cases of vessel resection and reconstruction in biliary tract cancer.

Exclusion Criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Locations
Country Name City State
Japan Osaka University, Graduate School of Medicine Osaka

Sponsors (1)
Lead Sponsor Collaborator
Kansai Hepatobiliary Oncology Group

Country where clinical trial is conducted

Japan, 

Outcome
Type Measure Description Time frame Safety issue
Primary Comparison of vascular invasion in diagnostic image and in pathology. 20 years No
Primary R0 resection rate 20 years No
See also
  Status Clinical Trial Phase
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Withdrawn NCT03110510 - FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT00380588 - Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer Phase 2
Terminated NCT00090025 - XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Phase 3
Terminated NCT04066491 - Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC Phase 2/Phase 3
Recruiting NCT05998447 - GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer Phase 2
Recruiting NCT03718897 - Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing
Recruiting NCT05056116 - A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer N/A
Recruiting NCT04692051 - A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer Phase 2
Terminated NCT04057365 - Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Phase 2
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Completed NCT02829918 - Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Phase 2
Recruiting NCT04584996 - CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers
Completed NCT02579616 - Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy Phase 2
Recruiting NCT05052099 - Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer Phase 1/Phase 2
Recruiting NCT01494363 - Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer Phase 2
Completed NCT00753675 - Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Phase 2
Terminated NCT00630890 - Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor) Phase 1
Recruiting NCT04445532 - Hepatobiliary Tumors Tissue Samples Acquisition